Integrative analysis of polo-like kinase family identifies a prognostic signature and validates PLK2 as a therapeutic target in glioma
Our study highlights the prognostic value of the PLK gene family in glioma and identifies PLK2 as a promising therapeutic target. The PLK2 inhibitor ON1231320 shows potential as an anti-GBM agent and warrants further investigation in preclinical and clinical studies.
Authors
- Chengjun Zheng
- Shuqing Yu (ORCID: https://orcid.org/0000-0001-8012-2398)
- Qiaodong Chen
- Zhaoshi Bao (ORCID: https://orcid.org/0000-0003-4922-4470)
- Yutong Feng
- Ying Zhang (ORCID: https://orcid.org/0000-0002-8531-1291)
- Fang Zheng (ORCID: https://orcid.org/0000-0002-2024-2424)
- Delong Zhang (ORCID: https://orcid.org/0000-0002-0555-9642)
Institutions
- Capital Medical University (CN)
- Beijing Tian Tan Hospital (CN)
- Beijing Institute of Neurosurgery (CN)
Publication Details
- Journal
- Translational Cancer Research
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/tcr-2025-1078
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00